Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

NCT ID: NCT06905834

Last Updated: 2025-04-04

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-30
• Study Completion Date: 2028-06-30

Brief Summary

This Phase IIB, multicenter, double-blind, randomized, and uncontrolled clinical trial aims to assess the efficacy and safety of subconjunctival injection of Mesenchymal Stem Cells (MSCs) in patients with Graft-versus-Host Disease (GVHD) and severe ocular involvement (DYD-dry eye disease). The primary objective is to evaluate the clinically and statistically significant improvement in the signs and symptoms associated with the disease.

Secondary objectives include:

• Analyzing adverse events related to the subconjunctival injection of MSCs to confirm the safety of this treatment in patients with GVHD ocular involvement.
• Identifying new biomarkers that can be used to objectively assess the progression of patients with GVHD and severe ocular involvement.
• Studying the relationship between the expression of ocular surface-specific markers by MSCs and their clinical efficacy, as well as the variation in the expression of these markers in relation to cell preservation methods.

Assessing the quality of life of patients treated with two doses of MSCs using the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire).

• Evaluating whether the cell dose impacts clinical improvement.

The trial includes 30 patients, divided into two groups of 15, and focuses on the assessment of dry eye disease, with the treatment based on MSC administration to improve clinical outcomes and quality of life for the patients.

Conditions

Dry Eye Disease (DED); Graft-Versus-Host Disease(GVHD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

6.25 million ASCs / 2,5ml of Ringer Lactato + 1% of HSA.

6.25 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.

Group Type: EXPERIMENTAL

Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC

Intervention Type: DRUG

Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.

12.5 million ASCs / 2,5 ml of Ringer Lactato + 1% of HSA.

12.5 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.

Group Type: EXPERIMENTAL

Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC

Intervention Type: DRUG

Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.

Interventions

Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC

Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients over 18 years of age who understand and sign the informed consent form.
• Diagnosis of severe GVHD (graft versus host disease) according to NIH criteria (revised by Lee SJ in 2017) with ocular involvement in the form of severe SOD (severe ocular disease) in both eyes for more than 3 months, objectively defined as superficial punctate keratitis >2 on the Oxford scale (range 0-5) and/or the presence of epithelial defect, and subjectively as severe symptoms, >33 points on the OSDI questionnaire (0-100).
• Patients must have previously been treated for at least three months with blood derivatives and/or insulin eye drops and topical cyclosporine or tacrolimus (unless any of these treatments were not tolerated and had to be discontinued).
• Patients must be using ocular lubricants at least 4 times a day and, despite this, still meet the criteria for severe SOD as outlined in point 2.
• Patients on low doses of topical corticosteroids for maintenance should have a stable dose for at least one month prior to inclusion.
• The dose and frequency of all topical medications the patient begins the trial with must remain unchanged throughout the duration of the trial, unless otherwise judged by the investigator.
• The chronic GVHD systemic treatment should be stable regarding the use of systemic immunosuppressors for at least one month prior to patient inclusion or before starting treatment.
• Negative result in the urine pregnancy test at the baseline visit for women of childbearing age. Subjects must be advised to use contraceptive methods during their participation in the clinical trial and undergo a new pregnancy test at the treatment visit if more than 28 days have passed since the baseline visit.

• Start of topical corticosteroid use within 4 weeks prior to inclusion.
• Cognitive impairments that could interfere with study compliance.
• Pregnant women or women during the lactation period.

Exclusion Criteria

• Uncontrolled systemic disease or any condition that, in the medical judgment, could put the patient at risk or affect the interpretation of the results.
• Uncontrolled systemic GVHD.
• Active ocular infection.
• Ocular surgery within the last 3 months.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Spanish Clinical Research Network - SCReN

NETWORK

Sponsor Role: collaborator

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

OTHER

Sponsor Role: collaborator

Instituto de Investigación Biomédica de Salamanca

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fermín Sánchez-Guijo Martín MD, PhD, Medical Degree in Haematology

Role: STUDY_DIRECTOR

Centro Asistencial Universitario de Salamanca (CAUSA)

Lourdes Vázquez López MD, PhD, Medical Degree in Haematology

Role: PRINCIPAL_INVESTIGATOR

Centro Asistencial Universitario de Salamanca (CAUSA)

Mi Kwon MD, PhD, Medical Degree in Haematology

Role: PRINCIPAL_INVESTIGATOR

Hospital General Universitario Gregorio Marañón (HGUGM)

Central Contacts

Esperanza Lopez Franco PhD, PhD in Molecular Biology

Role: CONTACT

uicec.coordinacion@ibsal.es

+34923291200 ext. 55779

Fátima Macho Sánchez-Simón, PhD in Neuroscience

Role: CONTACT

uicec-admon@ibsal.es

+34923291200 ext. 55145

Other Identifiers

2024-519772-10-00

Identifier Type: CTIS

Identifier Source: secondary_id

TERAV_24-01_EICRxEYE

Identifier Type: -

Identifier Source: org_study_id